News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nabi Biopharmaceuticals (NABI) Announces Receipt of $5 Million Milestone Payment



8/16/2011 10:00:58 AM

ROCKVILLE, Md., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) has received a $5 million payment from Fresenius USA Manufacturing, Inc. (Fresenius) that was triggered by the first commercial sale of Phoslyra, a milestone under the agreement governing the Company's 2006 sale of PhosLo® (calcium acetate) and related assets to Fresenius. These assets included the rights to a new liquid formulation of PhosLo that Fresenius has commercialized as Phoslyra

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES